(MENAFN Editorial) Dublin, Feb. 06, 2018 (GLOBE NEWSWIRE) -- The report has been added to ResearchAndMarkets.com's offering.

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies. Over the past five years, deal-making has occurred at a rapid pace, and regenerative medicine-focused biotech companies have drawn top dollar in both partnering and mergers and acquisitions.

The regenerative medicine market is undergoing many changes, and involves several modalities, from cell and gene therapies, to gene editing technologies, and tissue regeneration products. Devices, including tissue engineering products, currently dominate the marketed regenerative medicine portfolio, but this is expected to change as the pipeline for pharmaceuticals, namely cell and gene therapies, numbers in the thousands and includes a strong Phase II program as well as many novel candidates awaiting approval.

For the purposes of this report, the regenerative medicine market is broadly divided into device and therapy categories in the Key Company Players in Regenerative Medicine, Regenerative Medicine Approved Product Trends, and Regenerative Medicine Pipeline Trends chapters, followed by further market segmentation. The regenerative medicine device category includes biologic bone regenerative and repair devices, biologic soft tissue regeneration and repair devices, musculoskeletal scaffolds, and other tissue engineering products. The regenerative medicine therapy category covers cell therapies, gene therapies, and gene editing.

Key Topics Covered:

1 EXECUTIVE SUMMARY

2 THE REGENERATIVE MEDICINE LANDSCAPE

• Both the US and EU have specialized pathways for regenerative medicines
• Modalities in regenerative medicine
• Bibliography

3 KEY COMPANY PLAYERS IN REGENERATIVE MEDICINE

• Across the marketed product portfolio, many players are emerging as leaders
• Active developers in the pipeline include large and small companies
• Bibliography

4 REGENERATIVE MEDICINE APPROVED PRODUCT TRENDS

• Marketed products in regenerative medicine are dominated by devices
• Bone grafts and cell therapies account for the largest concentration of marketed regenerative medicines
• Musculoskeletal conditions lead the indications for approved or launched regenerative medicines
• Availability of launched regenerative medicine products varies between therapies and devices
• Bibliography

5 REGENERATIVE MEDICINE PIPELINE TRENDS

• The pipeline is being driven by cell and gene therapies
• Devices in development span multiple product types, but tend to focus on bone fractures and defects
• Early-stage research is supporting regenerative medicine therapies
• Noteworthy regenerative medicines are on the brink of approval
• In vivo gene therapies represent nearly one-third of the regenerative medicine pharmaceuticals pipeline
• The majority of regenerative medicines are in development for cancer or rare diseases
• The regenerative medicine product type employed varies across therapy areas
• Bibliography

6 DEAL-MAKING TRENDS IN REGENERATIVE MEDICINE

• Regenerative medicine financing trends
• Regenerative medicine mergers and acquisitions trends
• Regenerative medicine alliances trends
• Bibliography

7 APPENDIX

For more information about this report visit

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Biopharmaceuticals

MENAFN0602201800703653ID1096436116